title: A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma.
abstract: Non-small cell lung cancer can be classified into several histologic subtypes, most commonly lung adenocarcinoma (LADC) or squamous cell carcinoma (SqCC). With the introduction of targeted therapies that can result in dramatically different outcomes based on subtype, the importance of accurate classification has been amplified. Six antibodies (Napsin A, Desmoglein 3, TTF-1, CK5, p63, and tripartite motif-containing 29) were selected for evaluation on cases of LADC of lung SqCC. Guided by the sensitivities and specificities determined for individual antibodies, a protocol was developed using a sequential series of 2-antibody cocktails that resulted in the classification of 93% of cases with 100% specificity. Importantly, the initial step in this method, a napsin A+Desmoglein 3 antibody cocktail classified >85% of cases, resulting in <15% of cases requiring further evaluation beyond a single test. Two new antibodies specifically developed and optimized for the diagnosis of LADC and lung SqCC, a rabbit polyclonal Napsin A and a mouse monoclonal Desmoglein 3 [BC11], were the key elements of the antibody panel. Most importantly, the described protocol uses routine interpretation methods and an uncomplicated algorithm for classification. Given the increased difficulty of diagnosing poorly differentiated tumors, the ability of this 6-antibody panel to classify 96% and 87% of moderately and poorly differentiated cases, respectively, is of particular value, especially when limited tissue for molecular testing is an issue.
authors.affiliation: Biocare Medical, 4040 Pike Lane, Concord, CA 94520, USA. dtacha@biocare.net
authors.forename: David
authors.initials: D
authors.lastname: Tacha
authors.forename: Charie
authors.initials: C
authors.lastname: Yu
authors.forename: Ryan
authors.initials: R
authors.lastname: Bremer
authors.forename: Weiman
authors.initials: W
authors.lastname: Qi
authors.forename: Thomas
authors.initials: T
authors.lastname: Haas
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000465:Algorithms; D000818:Animals; D000906:Antibodies / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology* / Q000378:metabolism; D044963:Biopsy, Fine-Needle; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D016612:Paraffin Embedding; D011817:Rabbits; D011994:Recombinant Proteins / Q000276:immunology; D012107:Research Design; D012680:Sensitivity and Specificity; D016707:Tissue Fixation
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D011994:Recombinant Proteins